Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Department of Biostatistics and Bioinformatics, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Breast J. 2021 Apr;27(4):345-351. doi: 10.1111/tbj.14172. Epub 2021 Jan 25.
NCCN guidelines discourage the use of staging imaging for newly diagnosed patients with early breast cancer (BC). When performed, incidental radiologic findings of uncertain significance are often encountered. The purpose of this study was to compare incidental findings seen on staging imaging with distant recurrence in patients undergoing neo-adjuvant chemotherapy (NAC). 396 patients with BC who had NAC from 2008 to 2016 were identified from a prospectively maintained data base. Staging imaging was reviewed. Of 396 patients with BC treated with NAC, patients with a positive PET/CT for metastatic disease (n = 36, 9.1%), those that did not undergo staging imaging (n = 49, 12.4%), or those that did not have a reported incidental finding (n = 49, 12.4%) were excluded from analysis. Of the 262 patients who met criteria, mean age was 50 years (range: 26-88). 201 (76.7%) patients had stage I-II cancer, and 61 (23.3%) patients had stage III cancer. Overall, 146 (55.7%) patients had an incidental finding on imaging. 90 (34.4%) patients had one finding, 42 (16.0%) patients had two, and 14 (5.3%) patients had three or more findings. The majority of incidental findings were seen in the ovary/uterus (29.7%), followed by lung (18.4%), liver (10.3%), and bone (9.0%). 5 (3.4%) patients had additional imaging performed. At mean follow-up of 3.7 years (range: 0.7-10.8), 43 (15.6%) patients had a distant recurrence. Of these patients, only 5 (1.9%) patients had distant metastasis in the same organ that was initially thought to be an incidental finding. Our results suggest that breast cancer patients with incidental findings on preoperative staging imaging are unlikely to be indicative of sites for future metastasis.
NCCN 指南不鼓励对新诊断的早期乳腺癌(BC)患者进行分期影像学检查。但是,在进行检查时,通常会发现具有不确定意义的偶然放射学发现。本研究的目的是比较接受新辅助化疗(NAC)的患者分期影像学检查中偶然发现的结果与远处复发之间的关系。从 2008 年至 2016 年期间从一个前瞻性维护的数据中确定了 396 例接受 NAC 的 BC 患者。对分期影像学检查进行了审查。在 396 例接受 NAC 治疗的 BC 患者中,排除了 PET/CT 检查发现转移性疾病阳性(n=36,9.1%)、未进行分期影像学检查(n=49,12.4%)或未报告偶然发现(n=49,12.4%)的患者。符合标准的 262 例患者中,平均年龄为 50 岁(范围:26-88 岁)。201 例(76.7%)患者患有 I-II 期癌症,61 例(23.3%)患者患有 III 期癌症。总体而言,146 例(55.7%)患者的影像学检查发现偶然发现。90 例(34.4%)患者有一个发现,42 例(16.0%)患者有两个发现,14 例(5.3%)患者有三个或更多发现。大多数偶然发现的器官是卵巢/子宫(29.7%),其次是肺(18.4%)、肝脏(10.3%)和骨骼(9.0%)。有 5 例(3.4%)患者进行了额外的影像学检查。在平均 3.7 年的随访期间(范围:0.7-10.8 年),43 例(15.6%)患者发生远处复发。这些患者中,只有 5 例(1.9%)患者在最初认为是偶然发现的同一器官中出现远处转移。我们的结果表明,术前分期影像学检查中偶然发现的乳腺癌患者不太可能预示未来转移的部位。